A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic

The outbreak of opportunistic fungal infections such as mucormycosis has been a critical issue followingcoronavirus disease 19 (COVID-19). Mucormycosis is happened by the fungal group Mucorales and commonlyaffects immunocompromised patients. To date, COVID-19-associated mucormycosis (CAM) is being reportedin several countries. It should be noted that CAM has been started in patients approximately within two tothree weeks after the onset of COVID-19. However, here, in one case, fungal symptoms appeared after justone week. In patients with mucormycosis due to this enigmatic infection, the sinuses were most commonlyaffected, followed by the orbit, nose, and finally the brain. All cases received glucocorticoids as a part of viraltherapy. Diabetes mellitus (DM) was reported in all but one case in which COVID-19 was detected, without complications, and this may be the sole predisposing agent. Therefore, in this manuscript, we reported eightcases of COVID-19-induced mucormycosis. Although one case experienced evacuation of the right eye, othersdischarge with promising outcomes after receiving surgical debridement and proper anti-fungal treatmentincluding, amphotericin B, caspofungin, and posaconazole. J Pharm Care 2023; 11(3): 188-194